Combarnous F, Fouque D, Bernard N, Boulieu R, Chossegros P, Laville M, Zech P
Department of Nephrology, Hôpital Edouard Herriot, Lyon, France.
Eur J Clin Pharmacol. 1994;46(4):379-81. doi: 10.1007/BF00194410.
The pharmacokinetics of ganciclovir was evaluated in a 73-year old anuric, haemodialyzed patient given 1.25 mg.kg-1 at the end of each haemodialysis session, three times per week. A biexponential decrease in plasma ganciclovir was observed, with a peak concentration of 3.7 mg.l-1 followed by a steady state value of 2.6 mg.l-1 for almost 40 h. The total plasma clearance was 0.05 ml.min-1.kg-1, the volume of distribution at steady state was 0.6 l.kg-1, the elimination half life was 132 h, the area under curve was 372 micrograms.h.ml-1, the mean residence time was 190 h, and the percentage of ganciclovir cleared from plasma after a 5 h haemodialysis session was 52.1%. The simulated pharmacokinetics over one month, following the same scheme of administration, did not suggest marked accumulation of ganciclovir. These results were obtained after a reduction of 58% in the recommended dose in patients with impaired renal function.
对一名73岁的无尿血液透析患者的更昔洛韦药代动力学进行了评估，在每次血液透析结束时给予1.25mg.kg-1，每周三次。观察到血浆中更昔洛韦呈双指数下降，峰值浓度为3.7mg.l-1，随后在近40小时内稳态值为2.6mg.l-1。总血浆清除率为0.05ml.min-1.kg-1，稳态分布容积为0.6l.kg-1，消除半衰期为132小时，曲线下面积为372μg.h.ml-1，平均驻留时间为190小时，5小时血液透析后血浆中更昔洛韦清除百分比为52.1%。按照相同给药方案模拟的一个月药代动力学结果未显示更昔洛韦有明显蓄积。这些结果是在肾功能受损患者推荐剂量降低58%后获得的。
